Vectorite Biomedical Inc. (TPEX:4170)

Taiwan · Delayed Price · Currency is TWD

12.30

0.00 (0.00%)

Aug 4, 2026, 1:22 PM CST

Vectorite Biomedical Financials Overview

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	61.41	61.41	57.77	55.85	42.91	28.77
Revenue Growth	-9.56%	6.29%	3.43%	30.15%	49.16%	17.22%
Gross Profit	21.68	21.68	16.97	16.42	0.71	-2.47
Operating Income	-21.91	-21.91	-25.97	-16.13	-30.54	-42.43
Net Income	96.17	96.17	-40.05	-6.6	-26.41	8.36
Earnings Per Share	2.19	2.19	-0.92	-0.15	-0.60	0.19
EPS Growth	-	-	-	-	-	-

Revenue by Geography

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Taiwan	60.56	60.56	57.66	55.85	42.91	28.76
China	0.85	0.85	0.11	-	-	-
Total	61.41	61.41	57.77	55.85	42.91	28.77

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	170.61	170.61	184.9	203.67	213.52	239.38
Total Debt	0.39	0.39	-	-	-	-
Net Cash (Debt)	170.23	170.23	184.9	203.67	213.52	239.38
Net Cash Growth	-3.41%	-7.94%	-9.21%	-4.61%	-10.80%	167.28%
Net Cash Per Share	3.87	3.87	4.23	4.65	4.88	5.57

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	-5.79	-5.79	-11.51	1.3	14.7	-65.79
Capital Expenditures	-4	-4	-2.84	-4.76	-0.89	-1.8
Free Cash Flow	-9.78	-9.78	-14.35	-3.46	13.81	-67.59
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	35.31%	35.31%	29.37%	29.40%	1.65%	-8.60%
Operating Margin	-35.68%	-35.68%	-44.96%	-28.88%	-71.16%	-147.47%
Pretax Margin	156.57%	156.57%	-69.37%	-11.87%	-61.64%	28.95%
Profit Margin	156.62%	156.62%	-69.33%	-11.82%	-61.55%	29.05%
FCF Margin	-15.93%	-15.93%	-24.84%	-6.19%	32.19%	-234.93%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 4, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	5.94	6.37	-	-	-	74.32
P/FCF Ratio	-	-	-	-	44.96	-
PS Ratio	9.27	9.98	10.99	16.73	14.47	21.59